$20.32 Billion in Sales Expected for Johnson & Johnson (NYSE:JNJ) This Quarter

Wall Street brokerages forecast that Johnson & Johnson (NYSE:JNJ) will report $20.32 billion in sales for the current fiscal quarter, Zacks Investment Research reports. Four analysts have provided estimates for Johnson & Johnson’s earnings. The highest sales estimate is $20.40 billion and the lowest is $20.23 billion. Johnson & Johnson reported sales of $20.83 billion in the same quarter last year, which would suggest a negative year over year growth rate of 2.4%. The firm is scheduled to issue its next earnings report on Tuesday, July 16th.

On average, analysts expect that Johnson & Johnson will report full year sales of $81.20 billion for the current fiscal year, with estimates ranging from $80.90 billion to $81.56 billion. For the next financial year, analysts anticipate that the firm will post sales of $85.31 billion, with estimates ranging from $83.98 billion to $86.44 billion. Zacks Investment Research’s sales calculations are a mean average based on a survey of research firms that that provide coverage for Johnson & Johnson.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, April 16th. The company reported $2.10 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.03 by $0.07. Johnson & Johnson had a return on equity of 36.29% and a net margin of 17.99%. The business had revenue of $20.02 billion for the quarter, compared to the consensus estimate of $19.55 billion. During the same quarter in the prior year, the company earned $2.06 EPS. The business’s revenue was up .1% compared to the same quarter last year.



A number of equities analysts have recently issued reports on the company. Goldman Sachs Group assumed coverage on Johnson & Johnson in a research report on Tuesday, May 28th. They set a “buy” rating on the stock. Credit Suisse Group increased their price target on Johnson & Johnson from $152.00 to $156.00 and gave the stock an “outperform” rating in a research report on Thursday, May 16th. Wells Fargo & Co reissued an “outperform” rating and set a $157.00 price target (up previously from $152.00) on shares of Johnson & Johnson in a research report on Monday, May 6th. BMO Capital Markets raised their price objective on Johnson & Johnson from $154.00 to $157.00 and gave the company an “outperform” rating in a research report on Wednesday, April 17th. Finally, Morgan Stanley raised their price objective on Johnson & Johnson from $134.00 to $145.00 and gave the company an “equal weight” rating in a research report on Wednesday, April 17th. Four research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $147.30.

Shares of JNJ traded down $0.62 during midday trading on Friday, reaching $140.09. 6,548,091 shares of the stock were exchanged, compared to its average volume of 7,615,178. Johnson & Johnson has a 52 week low of $120.11 and a 52 week high of $148.99. The company has a current ratio of 1.44, a quick ratio of 1.13 and a debt-to-equity ratio of 0.47. The company has a market capitalization of $371.95 billion, a price-to-earnings ratio of 17.13, a PEG ratio of 2.42 and a beta of 0.70.

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, June 11th. Investors of record on Tuesday, May 28th were given a dividend of $0.95 per share. The ex-dividend date of this dividend was Friday, May 24th. This represents a $3.80 dividend on an annualized basis and a yield of 2.71%. This is an increase from Johnson & Johnson’s previous quarterly dividend of $0.90. Johnson & Johnson’s dividend payout ratio (DPR) is presently 46.45%.

In related news, Director Marillyn A. Hewson acquired 3,000 shares of the company’s stock in a transaction that occurred on Tuesday, June 11th. The shares were bought at an average price of $139.68 per share, with a total value of $419,040.00. Following the completion of the transaction, the director now directly owns 3,000 shares in the company, valued at $419,040. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.23% of the stock is owned by company insiders.

A number of hedge funds have recently modified their holdings of the stock. Evolution Wealth Advisors LLC acquired a new stake in Johnson & Johnson in the fourth quarter worth about $40,000. Horan Securities Inc. boosted its holdings in Johnson & Johnson by 122.3% in the fourth quarter. Horan Securities Inc. now owns 438 shares of the company’s stock worth $56,000 after acquiring an additional 241 shares in the last quarter. Stuart Chaussee & Associates Inc. boosted its holdings in Johnson & Johnson by 20.7% in the fourth quarter. Stuart Chaussee & Associates Inc. now owns 466 shares of the company’s stock worth $60,000 after acquiring an additional 80 shares in the last quarter. FNY Investment Advisers LLC boosted its holdings in Johnson & Johnson by 594.4% in the fourth quarter. FNY Investment Advisers LLC now owns 500 shares of the company’s stock worth $64,000 after acquiring an additional 428 shares in the last quarter. Finally, Thor Advisors LLC acquired a new stake in Johnson & Johnson in the first quarter worth about $69,000. 66.90% of the stock is currently owned by institutional investors.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Recommended Story: Does a trade war provide a risk to the global economy?

Get a free copy of the Zacks research report on Johnson & Johnson (JNJ)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.